Why titration is the default, not an option
Nobody starts retatrutide at a maintenance dose. Every published protocol ramps up gradually, because the gut side effects that come with GLP-1 triple agonists are dose-dependent and mostly happen in the first week or two at any new level. A titration schedule spreads that adjustment period over months instead of concentrating it into one rough week.
The general pattern
Most schedules follow the same shape even when the exact numbers differ: a low starting dose held for four weeks, then a step up, held again, repeated until reaching a target maintenance dose. The step size and the hold length are the two variables that change between a faster and a more cautious schedule.
What a typical table looks like
| Week | Dose | Notes |
|---|---|---|
| 1-4 | 2mg | Starting dose |
| 5-8 | 4mg | First step up |
| 9-12 | 8mg | Second step up |
| 13+ | 12mg (or held lower) | Maintenance range |
This mirrors the structure used in published trial arms, not a fixed instruction. Some people hold longer at a step if side effects haven’t settled; that’s a normal, reported variation.
Signs a step is being held too long or moved too fast
A schedule that never changes after months usually means someone settled at a dose that worked for them. A schedule where every step brings nausea that doesn’t fade before the next increase is often a sign the pace is faster than the body is adjusting to.
Where the schedule comes from
A legitimate UK listing that includes retatrutide with a certificate of analysis will often reference the dosing range used in trials, since that’s the only published data available. Treat any schedule that promises faster results at unusually high starting doses as a red flag rather than a shortcut.